Development of an

adeno-associated virus biopotency coagulation factor IX gene therapy

Journal

Molecular therapy. Methods & clinical development
ISSN: 2329-0501
Titre abrégé: Mol Ther Methods Clin Dev
Pays: United States
ID NLM: 101624857

Informations de publication

Date de publication:
12 Jun 2020
Historique:
received: 19 02 2020
accepted: 12 03 2020
entrez: 14 4 2020
pubmed: 14 4 2020
medline: 14 4 2020
Statut: epublish

Résumé

Gene therapy product release requires reliable and consistent demonstration of biopotency. In hemophilia B vectors, this is usually determined

Identifiants

pubmed: 32280725
doi: 10.1016/j.omtm.2020.03.013
pii: S2329-0501(20)30043-7
pmc: PMC7139127
doi:

Types de publication

Journal Article

Langues

eng

Pagination

581-588

Informations de copyright

© 2020 Shire International GmbH, now part of Takeda, Zurich, Switzerland.

Références

Mol Ther. 2008 Feb;16(2):280-9
pubmed: 18059373
Mol Ther. 2016 Feb;24(2):287-297
pubmed: 26437810
Genet Vaccines Ther. 2004 Jun 11;2(1):5
pubmed: 15193153
Blood. 1997 Nov 15;90(10):3962-6
pubmed: 9354664
Hum Gene Ther Methods. 2012 Feb;23(1):18-28
pubmed: 22428977
Gene Ther. 2001 Aug;8(16):1248-54
pubmed: 11509958
Hum Gene Ther. 2011 May;22(5):595-604
pubmed: 21410419
J Virol. 2009 Mar;83(6):2632-44
pubmed: 19109385
Ann N Y Acad Sci. 2001 Dec;953:64-74
pubmed: 11795424
J Virol. 2013 Dec;87(23):13035-41
pubmed: 24027330
Int J Hematol. 2013 Nov;98(5):525-32
pubmed: 24061775
Blood. 2001 Mar 1;97(5):1258-65
pubmed: 11222368
J Virol. 2013 Apr;87(8):4571-83
pubmed: 23408604
Blood. 2006 Apr 1;107(7):2653-61
pubmed: 16322469
Cell Rep. 2016 Nov 1;17(6):1657-1670
pubmed: 27806303
J Thromb Haemost. 2015 Jun;13 Suppl 1:S151-60
pubmed: 26149016
N Engl J Med. 2009 Oct 22;361(17):1671-5
pubmed: 19846852
Haemophilia. 2011 May;17(3):446-55
pubmed: 21299742
Acta Pharmacol Sin. 2004 Feb;25(2):196-202
pubmed: 14769209
Pharmeur Bio Sci Notes. 2018;2018:12-36
pubmed: 29845933
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5719-23
pubmed: 7777575
Hum Gene Ther Methods. 2012 Feb;23(1):1-7
pubmed: 22428975
J Virol. 2016 Jul 27;90(16):7019-7031
pubmed: 27147738
Atherosclerosis. 2009 May;204(1):121-6
pubmed: 18930458
N Engl J Med. 2011 Dec 22;365(25):2357-65
pubmed: 22149959
J Virol. 1998 Mar;72(3):1834-43
pubmed: 9499034
Pharm Res. 2001 Jul;18(7):922-7
pubmed: 11496950
Hum Gene Ther. 2015 Feb;26(2):69-81
pubmed: 25419787
EMBO J. 1990 Mar;9(3):869-78
pubmed: 1690125
Mol Ther Methods Clin Dev. 2018 Jun 28;10:29-37
pubmed: 30003118

Auteurs

Johannes Lengler (J)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Sogue Coulibaly (S)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Bernadette Gruber (B)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Reinhard Ilk (R)

Baxter AG, a member of the Takeda group of companies, Industriestraße 67, A-1221 Vienna, Austria.

Josef Mayrhofer (J)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Friedrich Scheiflinger (F)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Werner Hoellriegl (W)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Falko G Falkner (FG)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Hanspeter Rottensteiner (H)

Baxalta Innovations GmbH, a member of the Takeda group of companies, Uferstraße. 15, A-2304 Orth an der Donau, Austria.

Classifications MeSH